Search Results

Purespring Therapeutics is presenting preclinical data at the 61st European Renal Association Congress, showing that transgenes can be efficiently targeted to podocytes to replace defective genes or to use the podocyte as a protein factory to modulate kidney biology.

Palatin Technologies, Inc. today announced that it has entered into a warrant inducement agreement with an institutional investor to exercise certain outstanding warrants that the Company issued in November 2022 and October 2023 totaling 3,233,277 shares of the Company’s common stock for gross proceeds of approximately $6.1 million.

According to the Vision Research Reports, the global epigenetics market size was estimated at around USD 14.65 billion in 2023 and it is forecasted to be worth over USD 61.04 billion by 2033 with a CAGR of 15.34% from 2024 to 2033

RenovoRx, Inc. today announced that it has closed a private placement (the “private placement” or the “financing”) resulting in gross proceeds of approximately $6.1 million, before deducting offering expenses.